PMID- 29936475
OWN - NLM
STAT- MEDLINE
DCOM- 20181009
LR  - 20181202
IS  - 1791-7549 (Electronic)
IS  - 0258-851X (Print)
IS  - 0258-851X (Linking)
VI  - 32
IP  - 4
DP  - 2018 Jul-Aug
TI  - Association Between Imaging Findings of Airway Obstruction Adjacent to Lung 
      Tumors and the Onset of Interstitial Lung Disease After Nivolumab.
PG  - 887-891
LID - 10.21873/invivo.11324 [doi]
AB  - BACKGROUND: Compared to conventional cytotoxic chemotherapy, immune checkpoint 
      inhibitors have shown a significant efficacy in the treatment of lung cancer. 
      Although interstitial lung disease (ILD) is an important adverse event in 
      immunotherapy, risk factors for ILD remain unclear. PATIENTS AND METHODS: In this 
      multicenter cohort study (UMIN000025908), 201 patients who were treated with 
      nivolumab were retrospectively reviewed. Associations between the incidence of 
      ILD and patient characteristics were evaluated. ILD grade and progression-free 
      survival were analyzed according to the presence or absence of imaging findings 
      of airway obstruction adjacent to lung tumors (IAOT). RESULTS: In the 
      multivariate analysis, the odds ratio (OR) of ILD for patients with a history of 
      radiation pneumonitis or IAOT was 3.96 (p=0.012) and 6.59 (p=0.004), 
      respectively. ILD occurred in six (37.5%) out of 16 patients with IAOT and 19 
      (10.3%) out of 185 patients without IAOT. Three out of the six patients with ILD 
      and IAOT had ILD of grade 4 or more. The median progression-free survival of 
      patients with and without IAOT was 0.9 and 3.2 months, respectively (p<0.001). 
      CONCLUSION: IAOT was strongly associated with the occurrence of ILD after therapy 
      with nivolumab.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Nakahama, Kenji
AU  - Nakahama K
AD  - Department of Internal Medicine, National Hospital Organization Kinki-chuo Chest 
      Medical Center, Osaka, Japan nakahama_kenji@outlook.jp.
FAU - Tamiya, Akihiro
AU  - Tamiya A
AD  - Department of Internal Medicine, National Hospital Organization Kinki-chuo Chest 
      Medical Center, Osaka, Japan.
FAU - Isa, Shun-Ichi
AU  - Isa SI
AD  - Department of Thoracic Oncology, National Hospital Organization Kinki-chuo Chest 
      Medical Center, Osaka, Japan.
FAU - Taniguchi, Yoshihiko
AU  - Taniguchi Y
AD  - Department of Internal Medicine, National Hospital Organization Kinki-chuo Chest 
      Medical Center, Osaka, Japan.
FAU - Shiroyama, Takayuki
AU  - Shiroyama T
AD  - Department of Thoracic Malignancy, Osaka Prefectural Medical Center for 
      Respiratory and Allergic Diseases, Osaka, Japan.
FAU - Suzuki, Hidekazu
AU  - Suzuki H
AD  - Department of Thoracic Malignancy, Osaka Prefectural Medical Center for 
      Respiratory and Allergic Diseases, Osaka, Japan.
FAU - Inoue, Takako
AU  - Inoue T
AD  - Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, 
      Japan.
FAU - Tamiya, Motohiro
AU  - Tamiya M
AD  - Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, 
      Japan.
FAU - Hirashima, Tomonori
AU  - Hirashima T
AD  - Department of Thoracic Malignancy, Osaka Prefectural Medical Center for 
      Respiratory and Allergic Diseases, Osaka, Japan.
FAU - Imamura, Fumio
AU  - Imamura F
AD  - Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, 
      Japan.
FAU - Atagi, Shinji
AU  - Atagi S
AD  - Department of Thoracic Oncology, National Hospital Organization Kinki-chuo Chest 
      Medical Center, Osaka, Japan.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PL  - Greece
TA  - In Vivo
JT  - In vivo (Athens, Greece)
JID - 8806809
RN  - 0 (Antibodies, Monoclonal)
RN  - 31YO63LBSN (Nivolumab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Airway Obstruction/chemically induced/*diagnostic imaging/physiopathology
MH  - Antibodies, Monoclonal/administration & dosage/adverse effects
MH  - Cohort Studies
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Lung Diseases, Interstitial/chemically induced/*diagnostic 
      imaging/physiopathology
MH  - Lung Neoplasms/*diagnostic imaging/*drug therapy/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Nivolumab
MH  - Radiation Pneumonitis/diagnostic imaging/pathology
PMC - PMC6117789
OTO - NOTNLM
OT  - Airway obstruction
OT  - interstitial lung disease
OT  - lung cancer
OT  - nivolumab
OT  - risk factor
EDAT- 2018/06/25 06:00
MHDA- 2018/10/10 06:00
PMCR- 2018/07/03
CRDT- 2018/06/25 06:00
PHST- 2018/03/27 00:00 [received]
PHST- 2018/04/28 00:00 [revised]
PHST- 2018/05/02 00:00 [accepted]
PHST- 2018/06/25 06:00 [entrez]
PHST- 2018/06/25 06:00 [pubmed]
PHST- 2018/10/10 06:00 [medline]
PHST- 2018/07/03 00:00 [pmc-release]
AID - 32/4/887 [pii]
AID - 10.21873/invivo.11324 [doi]
PST - ppublish
SO  - In Vivo. 2018 Jul-Aug;32(4):887-891. doi: 10.21873/invivo.11324.